If you are interested in hearing about recent advances in Computational Psychiatry, visit the TCPW website!
Michael Browning
DPhil, MB.BS, MRCP, MRCPsych
Professor of Computational Psychiatry
- Professor
- Honorary Consultant Psychiatrist
I lead the Computational Psychiatry Lab in the Department of Psychiatry.
My research focuses on the role of learning in the aetiology and treatment of the emotional disorders (anxiety and depression). I also lead the NIHR TRC Mood Disorders Workstream, a network of 15 depression focused research clinics throughout the UK.
The emotional disorders are among the most common of the psychiatric illnesses. While there has been significant recent advances in understanding the cognitive and neural systems involved in producing symptoms of both anxiety and depression it is less clear why, when exposed to the same environment, some people will become anxious or depressed while others will not. The overall goal of my research is to better understand the mechanisms which lead to this vulnerability and to use this understanding to develop novel, evidence based treatments for these illnesses.
My work combines computational models of cognitive processes with physiological measures of neural function to unpick how patients learn and adapt to their environment. I also use pharamacological and cognitive techniques to modify the abnormal learning which is believed to cause anxiety and depression. I also run large scale clinical trials of the new treatments identified by this work.
I am a consultant psychiatrist with an honorary contract with Oxford Health NHS Trust. My clinical practice involves the assessment and treatment of patients with mood disorders, within the Oxford Depression Research Centre.
Recent publications
Noradrenaline causes a spread of association in the hippocampal cognitive map.
Journal article
Koolschijn RS. et al, (2026), Nat Commun
A Ketogenic Diet for Treatment-Resistant Depression: A Randomized Clinical Trial.
Journal article
Gao M. et al, (2026), JAMA Psychiatry
Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial.
Journal article
Łaszewska A. et al, (2026), Lancet Reg Health Eur, 61
Reduced striatal dopamine transmission as a transdiagnostic substrate of psychomotor retardation.
Journal article
Leong IL. et al, (2026), Brain, 149, 18 - 36
Corrigendum to "Pro-dopaminergic pharmacological interventions for anhedonia in depression: a living systematic review and network meta-analysis of human and animal studies", EBioMedicine. 2025 Nov;121:105967. doi: 10.1016/j.ebiom.2025.105967.
Journal article
Ostinelli EG. et al, (2026), EBioMedicine, 123
